Zoetis Inc.(ZTS)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #309 of 2,961 stocksTOP 25%
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
ZTS Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for Zoetis Inc. (ZTS), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ZTS at 68.6/100 on a 32-signal composite quality model, placing it at rank #309 of 2,961 stocks — the top 25% of the AI-ranked universe. ZTS scores in the top quartile across balance sheet strength (95.0), profitability (86.4), revenue scale (86.0). Areas of concern include revenue growth (36.7), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q2 2026), Zoetis Inc. reports quarterly revenue of $2.5B, net income of $691.0M, an operating margin of 35.1%. Top institutional holders of ZTS by reported 13-F value include BlackRock, VANGUARD CAPITAL MANAGEMENT, VANGUARD PORTFOLIO MANAGEMENT, based on the most recent SEC filings. ZTS trades on the NYSE exchange and files with the SEC under CIK 1555280. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ZTS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Zoetis Inc. directly from SEC EDGAR. Zoetis Inc.'s 13F Pro composite quality score has ranged between 67 and 80 since 2021, currently 68.6 — a declining long-term trajectory across 68 quarterly and live scoring snapshots.
What's Driving ZTS's Business? Latest 10-Q Breakdown
✓ 21/21 datapoints verifiedAI-extracted from Zoetis Inc.'s 10-Q filed 2026-08-06 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.
Revenue was roughly flat at $2.47B as an 11% drop in U.S. companion animal sales (Librela, Simparica Trio, dermatology under competitive pressure) offset 8% International growth, while a new securities class action targets the same flagship products.
Biggest Revenue Drivers
Companion animal revenue fell on softer demand, competitive pressure and generic competition, partially offset by livestock growth
Growth in parasiticides, diagnostics and mAb pain products plus cattle/poultry livestock demand, aided by FX
AI-extracted and verified against SEC EDGAR filing text. Not investment advice.
Revenue
Q2 2026
$2.5B
Net Income
Q2 2026
$691.0M
Free Cash Flow
Q2 2026
$538.0M
Operating Margin
Q2 2026
35.1%
ROIC
Q2 2026
28.4%
D/E Ratio
Q2 2026
2.87
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+2.3% YoYNet Income
+7.5% YoYEPS (Diluted)
+10.1% YoYTotal Assets
+8.8% YoYTotal Debt
+37.6% YoYOp. Cash Flow
-1.7% YoYFree Cash Flow
-0.7% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $9.47B +2.3% | $9.26B +8.3% | $8.54B +5.7% | $8.08B +3.9% | $7.78B +16.5% | $6.67B |
| Net Income | $2.67B +7.5% | $2.49B +6.1% | $2.34B +10.9% | $2.11B +3.8% | $2.04B +24.4% | $1.64B |
| EPS (Diluted) | $6.02 +10.1% | $5.47 +7.9% | $5.07 +12.9% | $4.49 +5.2% | $4.27 +24.9% | $3.42 |
| Total Assets | $15.49B +8.8% | $14.24B -0.3% | $14.29B -4.3% | $14.93B +7.4% | $13.90B +2.1% | $13.61B |
| Total Debt | $9.04B +37.6% | $6.57B +0.0% | $6.57B -16.9% | $7.90B +19.9% | $6.59B -8.4% | $7.20B |
| Operating Cash Flow | $2.90B -1.7% | $2.95B +25.5% | $2.35B +23.1% | $1.91B -13.6% | $2.21B +4.1% | $2.13B |
| Free Cash Flow | $2.28B -0.7% | $2.30B +41.8% | $1.62B +22.2% | $1.33B -23.6% | $1.74B +3.8% | $1.67B |
Get alerted when ZTS's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Zoetis Inc. including:
Top Institutional Holders of ZTS
BlackRock, Inc.
$2.8B39,430,181 shVANGUARD CAPITAL MANAGEMENT LLC
$1.9B26,027,984 shVANGUARD PORTFOLIO MANAGEMENT LLC
$1.7B23,860,445 shSTATE STREET CORP
$1.4B19,667,723 shSTATE FARM MUTUAL AUTOMOBILE INSURANCE CO
$1.1B15,892,903 shGEODE CAPITAL MANAGEMENT, LLC
$951.8M13,289,622 shWELLINGTON MANAGEMENT GROUP LLP
$677.2M9,423,895 shMORGAN STANLEY
$638.0M8,878,849 shNORDEA INVESTMENT MANAGEMENT AB
$471.7M6,592,578 shDEUTSCHE BANK AG\
$420.5M5,851,737 sh
| Fund | Value | Shares |
|---|---|---|
| BlackRock, Inc. | $2.8B | 39,430,181 |
| VANGUARD CAPITAL MANAGEMENT LLC | $1.9B | 26,027,984 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $1.7B | 23,860,445 |
| STATE STREET CORP | $1.4B | 19,667,723 |
| STATE FARM MUTUAL AUTOMOBILE INSURANCE CO | $1.1B | 15,892,903 |
| GEODE CAPITAL MANAGEMENT, LLC | $951.8M | 13,289,622 |
| WELLINGTON MANAGEMENT GROUP LLP | $677.2M | 9,423,895 |
| MORGAN STANLEY | $638.0M | 8,878,849 |
| NORDEA INVESTMENT MANAGEMENT AB | $471.7M | 6,592,578 |
| DEUTSCHE BANK AG\ | $420.5M | 5,851,737 |
Companies Similar to ZTS
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
BRISTOL MYERS SQUIBB CO
ABBOTT LABORATORIES
IDEXX LABORATORIES INC /DE
STRYKER CORP
Medtronic plc
VERTEX PHARMACEUTICALS INC / MA
WEST PHARMACEUTICAL SERVICES INC
REGENERON PHARMACEUTICALS, INC.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put ZTS on your watchlist
Track score changes the day Zoetis Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is ZTS a good stock to buy?
13F Pro's AI-powered analysis of Zoetis Inc. (ZTS) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ZTS are available on the ZTS stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. ZTS is classified as a large company.
Which hedge funds own ZTS?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ZTS. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Zoetis Inc.'s investment landscape.